Qrumpharma is structured around developing first-in-class therapeutics for the treatment of severe chronic and recurrent pulmonary infections and diseases, such as those caused by Nontuberculous Mycobacteria (NTM) and Tuberculosis. The firm's name - Qrumpharma - is derived from quorum sensing, in which colonies of bacteria can work together to be more successful than an individual. The team assembled by Qrumpharma includes experienced entrepreneurs working together to develop novel products and bring them to the market place.
